Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer  

作　　者：Guillermo Valenzuela Mauricio Burotto Katherine Marcelain Jaime Gonzalez-Montero 

机构地区：[1]Department of Basic and Clinical Oncology,University of Chile,Santiago 8380453,Chile [2]Department of Internal Medicine,Hospital del Salvador,Santiago 7500922,Chile [3]Department of Oncology,Bradford-Hill Clinical Research Center,Santiago 8420383,Chile

出　　处：《World Journal of Gastrointestinal Oncology》2022年第9期1654-1664,共11页世界胃肠肿瘤学杂志（英文版）（电子版）

基　　金：Supported by Agencia Nacional de Investigación y Desarrollo de Chile,Fondo Nacional de Investigación en Salud (FONIS),No. SA20I0059。

摘　　要：Colorectal cancer(CRC) is a major cause of mortality worldwide, associated with a steadily growing prevalence. Notably, the identification of KRAS, NRAS, and BRAF mutations has markedly improved targeted CRC therapy by affording treatments directed against the epidermal growth factor receptor(EGFR) and other anti-angiogenic therapies. However, the survival benefit conferred by these therapies remains variable and difficult to predict, owing to the high level of molecular heterogeneity among patients with CRC. Although classification into consensus molecular subtypes could optimize response prediction to targeted therapies, the acquisition of resistance mutations to targeted therapy is, in part, responsible for the lack of response in some patients. However, the acquisition of such mutations can induce challenges in clinical practice. The utility of liquid biopsy to detect resistance mutations against anti-EGFR therapy has recently been described. This approach may constitute a new standard in the decision algorithm for targeted CRC therapy.

关 键 词：Colorectal neoplasms Precision medicine Liquid biopsy CETUXIMAB PANITUMUMAB 

分 类 号：R735.34[医药卫生—肿瘤]